Vemurafenib inhibits immune escape biomarker BCL2A1 by targeting PI3K/AKT signaling pathway to suppress breast cancer

Overview of attention for article published in Frontiers in oncology, November 2022

Altmetric Badge

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 2 Dimensions

Readers on

mendeley: 4 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 23,814 followers.

Vemurafenib inhibits immune escape biomarker BCL2A1 by targeting PI3K/AKT signaling pathway to suppress breast cancer https://t.co/lCl7ltxpn8 https://t.co/TIyxRTMHJW

02 Dec 2022

Reply Repost Favourite

New research: Vemurafenib inhibits immune escape biomarker BCL2A1 by targeting PI3K/AKT signaling pathway to suppress breast cancer: Objectives To investigate the role of immune escape encoding genes on the prognosis of BC, and to predict the… https://t.c

29 Nov 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.